Biofrontera (BFRI) Stock: Buy, Sell, or Hold?
$0.91
-0.02 (-1.93%)
âŧ
5d:
+0.7%
30d:
+2.01%
90d:
-27.77%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (65%)
Quality Score
43/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$0.82 â $0.92
Position: SLIGHTLY HIGH
Forward P/E & Valuation
2.2x
CHEAP
vs 4.1x historical avg
Wall Street Target
$6.00
+546.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.80 / $0.95
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: BFRI is fairly priced but lacks strong directional signals. At -19.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When BFRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.47
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.53
40.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BFRI is currently trading at $0.91, which is considered slightly high relative to its 30-day fair value range of $0.82 to $0.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.2) compared to its historical average (4.1). Remarkably, the market is currently pricing in an annual earnings decline of 19.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BFRI is in a strong uptrend. Immediate support is located at $0.80, while resistance sits at $0.95.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+546.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BFRI is in a strong uptrend. Immediate support is located at $0.80, while resistance sits at $0.95.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+546.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.82 -
$0.92
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
Trading Range & Key Levels
30-Day Trading Range
$0.82 -
$0.92
Current vs Trading Range
SLIGHTLY HIGH
Support Level
$0.80
Resistance Level
$0.95
Current Trend
Strong Uptrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 546.6% below Wall St target ($6.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
2.16
Wall Street Target
$6.00
(+546.6%)
Revenue Growth (YoY)
32.9%
Profit Margin
-13.8%
Valuation Discount vs History
-19.0% cheaper
PE vs Historical
2.2 vs 4.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.0%
(market-implied from PE analysis)
1-Year Target
$0.84
(-10%)
2-Year Target
$0.75
(-19%)
3-Year Target
$0.68
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2â4)
$1.29
(+39%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.2 to 4.1
Stabilization Target:
$1.76
(+90.0%)
PE Expansion Potential:
+90.0%
Share BFRI Analysis
Share this live BFRI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (BFRI)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish StockTwits user believes that $BFRI management's heavy use of share-based compensation has given them a significant ownership stake in the company, which could contribute to a price increase above $1. This optimistic sentiment is currently the only market intelligence available.
Key Retail Themes:
management ownership
share price potential
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 2:13 PM ET
Data refreshes hourly during market hours. Next update: 3:13 PM
Data refreshes hourly during market hours. Next update: 3:13 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BFRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BFRI Research Pages
